Relay Therapeutics, Inc. (RLAY)

From the record

Relay Therapeutics, Inc.'s filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Relay Therapeutics, Inc.'s 6 filed years say what it did: revenue went from $83 million in fiscal 2020 to $15 million in fiscal 2025, down 28.6% a year; it rose in 2 of 5 years; the deepest fall was 98% from fiscal 2020 to fiscal 2022; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Relay Therapeutics, Inc. lost about 49 cents for every dollar of shareholders' money. Leverage: it owed about 9 cents per dollar of assets, and net share issuance: its share count grew 20.1% over the year (the filed statements).

From the record

Relay Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $15 million in fiscal 2025 ranks in the bottom 43% by size; a net margin of -1800.6% ranks in the bottom 28%; revenue growth of 123.2% a year over the last 3 filed years ranks in the top 12% (its annual reports).

From the record

Relay Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Patel, Sanjiv (President and CEO, as filed), filing under that title since 2020-07-15, 6.3 years (top 31% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 6.3 years (top 29%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 13%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Relay Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $85 million against no long-term debt tagged leaves 13.7% of its assets as net cash, bottom 20% of its family; cash from operations less capital spending is -1536.1% of revenue (bottom 23%); research spending of 1702.3% of revenue (top 21%) (its annual report).

From the record

Relay Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 123.2% a year over the last three filed years against -28.6% over all 6, speeding up (top 2% of its family); the newest year grew 53.5% (top 34%); research spending grew 2% a year (top 46%); capital spending grew -64.4% a year (bottom 16%) (its annual reports). Relay Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Relay Therapeutics, Inc.'s newest year against its own record: revenue of $15 million in fiscal 2025 came in 43% below the $27 million its prior three years' pace pointed to (bottom 18% of its family); net income of $276 million against a prior three-year average of $323 million (top 48%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 6%) (its annual reports).